Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Our Lady of Lourdes Regional Medical Center is embracing cutting-edge technology to transform how heart conditions are ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Saint Francis treated its first patient with pulsed-field ablation, which delivers pulsed electric fields to tissue to treat ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only one for which DOACs do not have a better risk profile ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

The Ordensklinikum Linz Elisabethinen is one of the first centers worldwide and the first center in Austria to use a new method for the treatment of ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

A New Pacemaker Algorithm for the Treatment of Atrial Fibrillation: Results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT) Electrophysiologic Characteristics of the Spontaneous Onset and ...

Dr. Ron Aviles explains available procedures and recovery time for those with heart and vascular conditions. Sponsored by Overlake Medical Center and Clinics.